Cargando…
Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research
Success in cancer immunotherapy depends on the identification and efficient targeting of specific tumor-associated antigens. Two pivotal strategies to prime patients’ immune system against malignant cells are tumor-specific adoptive T-cell therapy and tumor-specific vaccination. Here, we will focus...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Master Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614679/ https://www.ncbi.nlm.nih.gov/pubmed/23675044 |
_version_ | 1782264891375091712 |
---|---|
author | Schumacher, Thomas Ruehland, Claus Schultheiss, Christine Brinkman, Marc Roedel, Franz Reiser, Christian O. A. Hess, Juergen Reichel, Christoph |
author_facet | Schumacher, Thomas Ruehland, Claus Schultheiss, Christine Brinkman, Marc Roedel, Franz Reiser, Christian O. A. Hess, Juergen Reichel, Christoph |
author_sort | Schumacher, Thomas |
collection | PubMed |
description | Success in cancer immunotherapy depends on the identification and efficient targeting of specific tumor-associated antigens. Two pivotal strategies to prime patients’ immune system against malignant cells are tumor-specific adoptive T-cell therapy and tumor-specific vaccination. Here, we will focus on immunotherapeutic vaccination and discuss the advantages and disadvantages of different strategies to deliver tumor-specific T-cell epitopes. A particular focus will be put on virus-like particles (VLPs) as vehicle to deliver tumor-specific epitopes in the context of full-length proteins, as multi-epitope constructs or as individual tumor-associated T-cell epitopes. VLPs represent non-infectious and non-replicating antigen delivery systems devoid of any nucleic acid. They constitute innovative immunotherapeutic agents against cancer due to their superior, adjuvant-like antigenicity. We will present various tumor-associated antigens currently in different stages of development including survivin, as promising candidates for targeted tumor therapies. |
format | Online Article Text |
id | pubmed-3614679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Master Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36146792013-05-01 Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research Schumacher, Thomas Ruehland, Claus Schultheiss, Christine Brinkman, Marc Roedel, Franz Reiser, Christian O. A. Hess, Juergen Reichel, Christoph Int J Biomed Sci Article Success in cancer immunotherapy depends on the identification and efficient targeting of specific tumor-associated antigens. Two pivotal strategies to prime patients’ immune system against malignant cells are tumor-specific adoptive T-cell therapy and tumor-specific vaccination. Here, we will focus on immunotherapeutic vaccination and discuss the advantages and disadvantages of different strategies to deliver tumor-specific T-cell epitopes. A particular focus will be put on virus-like particles (VLPs) as vehicle to deliver tumor-specific epitopes in the context of full-length proteins, as multi-epitope constructs or as individual tumor-associated T-cell epitopes. VLPs represent non-infectious and non-replicating antigen delivery systems devoid of any nucleic acid. They constitute innovative immunotherapeutic agents against cancer due to their superior, adjuvant-like antigenicity. We will present various tumor-associated antigens currently in different stages of development including survivin, as promising candidates for targeted tumor therapies. Master Publishing Group 2007-09 /pmc/articles/PMC3614679/ /pubmed/23675044 Text en © Thomas Schumacher et al. Licensee Master Publishing Group http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Schumacher, Thomas Ruehland, Claus Schultheiss, Christine Brinkman, Marc Roedel, Franz Reiser, Christian O. A. Hess, Juergen Reichel, Christoph Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research |
title | Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research |
title_full | Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research |
title_fullStr | Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research |
title_full_unstemmed | Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research |
title_short | Advanced Antigen Delivery of Murine Survivin: Chimeric Virus-Like Particles in Cancer Vaccine Research |
title_sort | advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine research |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614679/ https://www.ncbi.nlm.nih.gov/pubmed/23675044 |
work_keys_str_mv | AT schumacherthomas advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch AT ruehlandclaus advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch AT schultheisschristine advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch AT brinkmanmarc advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch AT roedelfranz advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch AT reiserchristianoa advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch AT hessjuergen advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch AT reichelchristoph advancedantigendeliveryofmurinesurvivinchimericviruslikeparticlesincancervaccineresearch |